Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Product: | Constella |
| Active Ingredient: | Linaclotide 0.072mg |
| Dosage Form: | Capsule |
| New Zealand Sponsor: | Allergan New Zealand Limited |
| Manufacturer: | Forest Laboratories Ireland Limited, Dublin, Ireland |
| Product: | Constella |
| Active Ingredient: | Linaclotide 0.145mg |
| Dosage Form: | Capsule |
| New Zealand Sponsor: | Allergan New Zealand Limited |
| Manufacturer: | Forest Laboratories Ireland Limited, Dublin, Ireland |
| Product: | Constella |
| Active Ingredient: | Linaclotide 0.29mg |
| Dosage Form: | Capsule |
| New Zealand Sponsor: | Allergan New Zealand Limited |
| Manufacturer: | Forest Laboratories Ireland Limited, Dublin, Ireland |
| Product: | RINVOQ |
| Active Ingredient: | Upadacitinib hemihydrate 15.4mg |
| Dosage Form: | Modified release tablet |
| New Zealand Sponsor: | AbbVie Limited |
| Manufacture: | AbbVie Ireland NL B.V., Sligo, Ireland |
Dated this 13th day of November 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).